Overall, our results indicate that the PDE4 inhibitor Roflumilast, a medicine used in the treatment of severe chronic obstructive pulmonary disease or psoriasis, counteracts high-dose irradiation-induced endothelial dysfunctions and preserves the functional integrity of the microvascular endothelium [33,34]. Here, PDE4A is linked to psoriasis.